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Introduction: Southern Africa is home to one of the largest populations with Human 
Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome (HIV/ AIDS). 
Although morbidity and mortality rates have reduced with the advent of Highly Active 
Antiretroviral Therapy (HAART), long-term use may lead to metabolic complications 
such as insulin resistance, lipodystrophy and dyslipidaemia. These adverse-effects are the 
components of metabolic syndrome (MetS), associated with an increased risk of 
cardiovascular disease and type 2 diabetes. Continuous efforts are being made to improve 
the quality of life of HIV/ AIDS patients whilst controlling the disease state. The 
introduction of a fixed-dose combination (FDC) pill (EFV/FTC/TDF) as first-line 
treatment ensures a more favourable side-effect profile, decreased pill burden and 
improved adherence.  
 
Aims and Objectives: To investigate the incidence and prevalence of metabolic 
syndrome in HIV patients on HAART triple therapy compared to a fixed-dose 
combination. To investigate the impact of a single pill compared to triple therapy on the 
incidence and prevalence of metabolic syndrome in patients on HAART. 
 
Method: Data was collected as a retrospective chart review upon obtaining gatekeeper’s 
permission from Addington Hospital. Questionnaires were used as a collection tool for 
demographic and anthropometric data in a total of 350 patients. Patients were divided 
according to HAART regimens, FDC (A) and triple therapy (B). The joint interim 
statement by the International Diabetes Federation Task Force on Epidemiology and 
Prevention, National Heart Lung and Blood Institute, American Heart Association, World 
Health Organisation, International Atherosclerosis Society and International Association 
for the Study of Obesity was used to define the metabolic syndrome. 
 
Results: Of the patients studied, 62.6% were female and 37.4% male. The overall 
prevalence of MetS was 16.6%. There was a significant association between HAART 
regimen and MetS (p = 0.001). There was a higher prevalence of MetS among triple 
therapy patients (23.4%) compared to FDC (9.7%). When adjusted for age, gender, 
comorbidities and patient markers, the multivariable logistic regression found HAART 
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regimen, glucose, BMI, and the presence of comorbidities to be significant predictors of 
MetS. 
 
Conclusion: Patients on triple therapy had 3 times the odds of developing MetS 
compared to those on FDC. Increased levels of blood glucose, Low-Density Lipoprotein 
cholesterol (LDL-c), systolic and diastolic blood pressure were significantly positively 
associated with triple therapy. 
ix	  	  
 







TABLE OF CONTENTS…………………………………………………….. ix 
LIST OF ABBREVIATIONS………………………………………………... xi 
LIST OF FIGURES…………………………………………………………... xiii 
LIST OF TABLES……………………………………………………………. xiv 
  
CHAPTER ONE: INTRODUCTION.………………………………………. 1 
1.1 HIV/ AIDS Epidemiology…………………………………………………. 1 
1.2 HAART Initiation and Regimens………………………………………….. 2 
1.3 Fixed-Dose Combination Antiretroviral Therapy…………………………. 4 
1.4 Adverse-effects of HAART………………………………………………... 5 
1.4.1 Nonnucleoside reverse transcriptase inhibitors………………………. 5 
1.4.2 Nucleotide and nucleoside reverse transcriptase inhibitors…………... 6 
1.4.3 Protease inhibitors…………………………………………………….. 8 
1.4.4 Integrase inhibitors……………………………………………………. 8 
1.4.5 CCR5 antagonists………..…………………………………………… 9 
1.4.6 Fusion inhibitor………………………………………………………... 9 
1.5 Metabolic Syndrome………………………………………………………... 9 
1.6 Clinical Criteria for Diagnosing Metabolic Syndrome……………………... 10 
1.7 Global Prevalence of MetS…………………………………………………. 12 
1.8 Components of MetS in HIV patients on HAART…………………………. 13 
1.8.1 Abnormal fat distribution……………………………………………... 13 
1.8.2 Dyslipidaemia…………………………………………………………. 17 
1.8.3 Insulin resistance and glucose intolerance…………………………….. 18 
1.8.4 Elevated blood pressure……………………………………………….. 21 
1.9 Aims of Study………………………………………………………………. 22 
1.10 Objectives of Study………………………………………………………... 22 
  
CHAPTER TWO: MATERIALS AND METHODS………………………... 23 
2.1 Ethical Approval……………………………………………………………. 23 
2.2 Study………………………………………………………………………... 23 
2.3 Location…………………………………………………………………….. 23 
2.4 Sample Size…………………………………………………………………. 23 
2.5 Inclusion Criteria…………………………………………………………… 24 
2.6 Exclusion Criteria…………………………………………………………... 24 
2.7 Criteria for MetS……………………………………………………………. 24 
2.8 Data Capture………………………………………………………………... 24 
2.9 Analysis…………………………………………………………………….. 25 
  
CHAPTER THREE: RESULTS……………………………………………... 26 
3.1 Age………………………………………………………………………….. 26 
3.2 Gender………………………………………………………………………. 27 
x	  	  
3.3 Ethnicity…………………………………………………………………….. 28 
3.4 Regimen…………………………………………………………………….. 29 
3.5 Comorbidities……………………………………………………………….. 30 
3.6 Current Medication…………………………………………………………. 31 
3.7 Mean Values of Clinical Markers…………………………………………... 33 
3.8 Prevalence of Metabolic Syndrome………………………………………… 40 
3.9 Individual factors compared to MetS……………………………………….. 41 
3.10 Atherogenic Index of Plasma (AIP) ……………………………………… 47 
  
CHAPTER FOUR: DISCUSSION AND CONCLUSION………………….. 48 
4.1 Demographics………………………………………………………………. 48 
4.2 Patient Groups (FDC and TT) ……………………………………………… 49 
4.3 Metabolic Syndrome……………………………………………………….. 50 
4.4 Comorbidities and Current Medication……………………………………. 51 
4.5 Clinical Markers……………………………………………………………. 52 
4.5.1 Glucose…………………………………………….………………….. 53 
4.5.2 HDL-c,Triglycerides and Atherogenic index of plasma………..……... 53 
4.5.3 Body Mass Index……………………………………………………… 55 
4.5.4 Blood Pressure. ………………………………………………………. 56 
4.6 Management……………………………………………………………….. 56 
4.7 Conclusion………………………………………………………………….. 57 




Appendix 1…………………………………………………………………. 70 
Appendix 2…………………………………………………………………. 71 
Appendix 3..………………………………………………………………… 73 
Appendix 4…………………………………………………………………. 74 













LIST OF FIGURES 
 
Figure 1: Age distribution among patients on FDC and TT……………………. 26 
Figure 2: Gender distribution among patients on FDC and TT………………… 27 
Figure 3: Ethnic profiling of patients on FDC and TT…………………………. 28 
Figure 4: Number of patients on variations of triple therapy regimens………… 29 
Figure 5: Distribution of patients with comorbidities…………………………... 30 
Figure 6: Number of patients on additional medication………………………... 31 
Figure 7: Current medication combinations…………………………………….. 32 
Figure 8: Mean random blood glucose (mmol/L) ……………………………… 33 
Figure 9: Mean fasting total cholesterol (mmol/L).…………………………….. 34 








Figure 12: Mean triglyceride readings among FDC and TT groups……………. 37 
Figure 13: Mean Body Mass Index (BMI) among FDC and TT groups……….. 38 




Figure 15: Prevalence of metabolic syndrome (MetS) ………………………… 40 
Figure 16: Prevalence of MetS in males and females…………………………... 41 
Figure 17: Prevalence of MetS different age groups…………………………… 41 
Figure 18: Prevalence of MetS among different ethnicities……………………. 42 
Figure 19: Prevalence of MetS in the presence of comorbidities………………. 43 
Figure 20: Prevalence of MetS among individual comorbidities………………. 44 
Figure 21: Prevalence of MetS with concomitant medication………………….. 45 
Figure 22: Prevalence of MetS among categories of BMI……………………… 46 
Figure 23: Mean AIP values in the FDC and TT groups over a 3-year period…. 47 
 
xii	  	  
LIST OF TABLES 
 
Table 1: Examples of drugs under the different classes of Antiretroviral drugs…….. 2 
Table 2: South African guidelines for HAART regimens. First-line Regimen……… 3 
Table 3: South African guidelines for HAART regimens. Second-line Regimen…... 3 
Table 4: Clinical markers used to diagnose metabolic syndrome by different bodies. 10 
Table 5: Prevalence of metabolic syndrome in HAART patients by studies 
conducted in different countries…………………………………………. 
 
12 






LIST OF ABBREVIATIONS 
 
ABC    Abacavir 
AIDS     Acquired Immune Deficiency Syndrome 
AIP    Atherogenic Index of Plasma 
ATP III   Adult Treatment Panel III 
ATV    Atazanavir 
BMI    Body Mass Index 
BP    Blood Pressure 
CI    Confidence Interval 
CLAT    Cryptococcal Latex Antigen Test 
CrAG    Cryptococcal Antigen 
CRABP-1   Cellular Retinoic Acid Binding Protein 1 
d4T    Stavudine 
DLV    Delavirdine 
DM    Diabetes Mellitus 
DRV    Darunivir 
EFV    Efavirenz 
ETR    Etravirine 
FDC    Fixed-Dose Combination 
FFA    Free Fatty Acids 
FTC    Emtricitabine 
HAART    Highly Active Antiretroviral Therapy 
HALS    HIV Associated Lipodystrophy Syndrome  
HDL-C   High-Density Lipoprotein Cholesterol 
HIV     Human Immunodeficiency Virus 
HPT    Hypertension 
IDF    International Diabetes Federation 
IDV    Indinavir 
IL-6     Interleukin-6 
IR    Insulin Resistance 
LDL-c    Low-Density Lipoprotein Cholesterol 
xiv	  	  
LPV    Lopinavir  
MCP-1   Monocyte Chemoattractant Protein 1 
MetS    Metabolic Syndrome 
mtDNA   Mitochondrial Deoxyribonucleic Acid 
MVC    Maraviroc 
NVP    Nevirapine 
OR    Odds Ratio 
RAL    Raltegravir 
RTV    Ritonavir 
SD    Standard Deviation 
SQV    Saquinavir 
3TC    Lamivudine 
TB    Tuberculosis 
TDF    Tenofovir 
TG    Triglyercides 
TNF-α    Tumor Necrosis Factor Alpha 
TT    Triple Therapy 
WHO    World Health Organisation    




CHAPTER ONE: INTRODUCTION 
 
1.1 HIV/ AIDS Epidemiology  
 
Human immunodeficiency virus/ Acquired Immune Deficiency Syndrome (HIV/ AIDS) 
immensely contributes to disease burden in South Africa with an estimated total of 7.03 
million people and approximately one in five women of reproductive age living with the 
disease in 2016 [1]. However, the rate of infections in the general population has decreased 
from 1.27% in 2002 to 1.22% in 2016 [1].  
 
Highly Active Antiretroviral Therapy (HAART), used in the treatment of HIV-1 
infections, was initiated in the 1990s. This has aided in slowing down the disease 
progression from a fatal one to a chronic condition leading to a decrease in morbidity and 
mortality in these patients [2, 3]. HAART consists of a combination of at least 3 drugs 
falling in different classes, depending on their mechanism of action [3]. Clinical evidence 
suggests that there is a reduction in mortality in patients with a CD4 count of < 350 
cells/μL who start antiretroviral therapy without delay [4]. The national rollout programme 
of HAART began in 2005, with at least one service point per district in South Africa. This 
led to the successful decline in the number of AIDS-related deaths from 325, 241 in 2006 
to 150, 759 in 2016 [1].  
 
The goals of HAART are to: improve quality of life, reduce HIV- related morbidity and 
mortality, provide maximum and durable suppression of viral load and restore or preserve 
immune function. Antiretroviral agents currently available and approved for use fall into 
the following classes: [4] 
• Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI) 
• Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) 
• Protease Inhibitors (PI) 
• Integrase Inhibitors (INSTI) 





Table 1: Examples of drugs under the different classes of Antiretroviral drugs [4, 5, 7] 
 























Dolutegravir Aplaviroc  




   
Emtricitabine 
(FTC) 
 Indinavir (IDV)    
Abacavir (ABC)  Darunavir 
(DRV) 
   
 
1.2 HAART Initiation and Regimens 
 
Previously, HAART initiation required a patient’s HIV status to be confirmed and then 
assessed against the World Health Organisation (WHO) clinical staging. A CD4 count 
was used to determine eligibility of HAART: initiation (CD4 ≤ 500 µl), prioritisation 
(CD4 ≤ 350 µl), fast tracking (CD4 ≤ 200 µl) or Cryptococcal Antigen or Cryptococcal 
Latex Antigen Test (CD4 ≤ 100 µl) [8]. If the CD4 count was ≤ 500 µl, HAART was 
initiated regardless of clinical staging, and if HIV was advanced or severe (WHO stage 3 
or 4) then HAART is initiated regardless of CD4 counts [8]. However, new WHO 
guidelines recommend a “treat-all” approach, removing limitations on eligibility. This 
recommendation dictates that all age groups and populations are eligible for HAART 
initiation regardless of CD4 count or WHO clinical staging [6]. 
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As per the 2016 WHO consolidated guidelines on HAART use, the first-line treatment for 
adults should include 2 NRTIs plus a NNRTI or INSTI [6]. The preferred first-line drugs 
for HAART initiation are TDF + 3TC or FTC + EFV as a combination (based on body 
weight and if there are no contraindications). By the end of 2014, almost 70% of the 
global population were on this first-line regimen and only 60% were taking it as a fixed-
dose combination (FDC). This specific regimen was chosen, with moderate quality 
evidence suggesting that it is less frequently associated with severe adverse events and 
has better virological suppression and treatment response as compared to NNRTI (once or 
twice daily dosing) or PI-based regimens [6]. South African HAART regimen guidelines 
are adapted from international guidelines and appear below (refer to table 2 and 3). 
 
Table 2: South African Guidelines for HAART Regimens [8] - First-line Regimen 
New initiation for: adolescents > 15 years 
weighing > 40 kg, adults, all HIV/TB co-
infection, all HBV co-infection 
TDF + 3TC (or FTC) + EFV as a fixed-
dose combination 
EFV Contraindication* TDF + 3TC (or FTC) + NVP or LPV/r 
TDF Contraindication** ABC + 3TC + EFV or NVP 
* EFV contraindication may manifest as: intolerance to EFV, significant psychiatric comorbidity and interference with 
daily function. 
** There is a TDF contraindication if there is a creatinine clearance of < 50mL/min. 
No patients should be on d4T, pre-existing patients to be changed to TDF.  
A patient is considered for a second-line regimen if there is virological failure (viral load 
> 1000 copies/mL) on at least two occasions, occurring for two months regardless of 
patient adherence.  
 
Table 3: South African Guidelines for HAART Regimens [8] - Second-line Regimen 
Failure on a TDF- based regimen AZT + 3TC + *LPV/r 
AZT + TDF + 3TC + LPV/r (if HBV co-
infected) 
Failure on d4T or AZT based regimen TDF + 3TC (or FTC) + LPV/r 
Dyslipidaemia (total cholesterol > 6mmol/L) Change LPV/r to ATV/r 
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or diarrhoea associated with LPV/r  
Anaemia or renal failure Change to ABC 
*LPV/r: Combination of lopinavir with ritonavir. Extensive toxicity and a high pill burden have discouraged the use of 
ritonavir on its own in a PI-based regimen. Ritonavir had been used as a boosting agent after it was found to change the 
pharmacokinetic parameters of the PI to which it is added. These parameters include: area under the curve, maximum 
concentration, minimum concentration and half-life. Boosted ritonavir leads to inhibition of hepatic and intestinal 
cytochrome P450 3A, resulting in a significant improvement in the bioavailability and half-life of PIs [9]. Low-dose 
ritonavir is used and enhances exposure to the concomitant PI without markedly adding to the side-effect profile of the 
regimen. Boosted therapy has been successful in maintaining high levels of viral suppression in both HAART- naïve 
and those failing on other HAART regimens [9, 10]. 
 
A third-line ad-hoc committee of experts is required to review patients failing on second-
line regimens. Patients on PIs for at least a year with inadequate virological suppression 
are eligible for genotype resistance testing. Third-line regimens comprise of: Raltegravir, 
Darunavir/Retravirine, specifically tailored as per patient history and genotype 
interpretation [8]. 
 
1.3 Fixed-Dose Combination (FDC) Antiretroviral Therapy 
A fixed-dose combination is a combination of two or more active pharmaceutical 
ingredients in a single pill [11]. The first-line FDC antiretroviral drug rolled out in South 
Africa contains: efavirenz (EFV), emtricitabine (FTC) and tenofovir (TDF) [12]. In 2013, 
new ART guidelines required that all newly initiated patients, as well as pregnant patients 
regardless of CD4 count and provided they are tolerant, should be started on the 
EFV/FTC/TDF fixed-dose combination [13]. However, patients who fail on first-line 
regimen and those weighing < 40 kg are to be excluded. Patients weighing < 40kg require 
a lower doses of EFV (400 mg) as opposed to the 600 mg formulated in the FDC. Lower 
dose EFV is required as clearance is affected by body weight. A higher body weight is 
associated with a decrease in EFV plasma concentration [14]. The dosage may be changed 
to the EFV/FTC/TDF FDC combination once patients regain the weight [13]. 
HAART regimens are generally complex with a high pill burden, frequent dosing, drug-
drug interactions and various food requirements. Adverse events are common with 
HAART and may lead to discontinuation in early phases of therapy, dose interruptions, 
and significant reductions in the quality of life [15, 16, 21]. Discontinuation and 
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noncompliance have serious consequences as they may lead to the emergence of 
resistance [17]. Efforts are continuously being made to simplify regimens and ensure that 
undesirable adverse-effects are kept to a minimum [18]. 
The fixed-dose combination of EFV/FTC/TDF is bioequivalent to the administration of its 
individual components [19]. The side-effect profile for the EFV/FTC/TDF combination is 
similar to that of its individual components [13]. A study done by Pozniak et al. showed 
that the fixed-dose combination of EFV/FTC/TDF was superior in achieving and 
maintaining an HIV RNA level < 400 copies/ml and an increase in CD4 cells when 
compared to a fixed-dose zidovudine/lamivudine and efavirenz over a 96-week period [20].  
 
EFV/FTC/TDF is suggested to be advantageous as it reduces the pill burden thereby 
improving adherence. It is comparatively cost effective when compared to the triple drug 
regimen [13]. Reports on patients receiving the EFV/FTC/TDF fixed-dose combination 
showed that 64% of patients thought the new regimen was “much better” than their 
previous regimen by week 4, and by week 48 this number increased to 85% [21]. 
 
Patients have shown significantly higher adherence (> 95%) with a once daily tablet 
regimen than multiple tablet regimens. This, in turn, is associated with a lower risk of 
hospitalization and reduction of inpatient costs [22].  
 
1.4 Adverse- effects of HAART 
 
Long-term exposure to HAART is associated with toxicities that are making it 
increasingly difficult to successfully manage HIV-infected patients [23].  Deleterious 
adverse-effects may be experienced by up to 50% of patients with the most common 
being: rash, hypersensitivity reaction, anaemia, gastrointestinal (GI) discomfort, jaundice, 
and undesirable effects on the central nervous system (CNS). Gastrointestinal side-effects 
include diarrhoea, nausea, and vomiting [5, 15, 24].  
1.4.1 Nonnucleoside reverse transcriptase inhibitors (NNRTI) 
NNRTIs (EFV, NVP, ETR) inhibit the activity of reverse transcriptase directly and 
suppress HIV replication. All drugs in this class are associated with: rash (including 
Steven Johnson Syndrome), hepatotoxicity and drug-drug interactions [5]. Nevirapine 
(NVP) use is most commonly associated with the development of a rash, which may be 
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life threatening, requiring discontinuation in approximately 5% of patients. The rash may 
be life-threatening if accompanied by fever and systemic hypersensitivity, especially 
hepatitis [5]. NNRTIs significantly increase plasma High-Density Lipoprotein cholesterol 
(HDL-c) levels. NVP containing antiretroviral regimens are associated with better lipid 
profiles due to the fact that they cause increased plasma concentrations of HDL-c [25].  
EFV is commonly associated with adverse-effects affecting the central nervous system. 
These effects occur most commonly within 2-6 weeks of therapy. Central nervous 
disturbances may manifest as: abnormal/ vivid dreams, dizziness, headache, insomnia, 
somnolence, impaired concentration, and mania. These reactions may occur in as many as 
40% of patients [5, 26].  
ETR is associated with the development of a rash and hepatotoxicity [29]. NNRTIs are not 
generally associated with GI toxicity [29]. 
1.4.2 Nucleoside and nucleotide reverse transcriptase inhibitors (NRTI) 
The drugs in this class are nucleoside or nucleotide (TDF) analogues that act as false 
substrates for reverse transcriptase and terminate the viral DNA chain elongation [5]. 
Major toxicities of NRTI therapy are thought to be secondary to inhibition of 
mitochondrial DNA polymerase [26, 27]. Long-term use can result in lactic acidosis or 
symptomatic hyperlactataemia, as a result of mitochondrial toxicity [5]. Mechanisms of 
NRTI-induced mitochondrial toxicity include competitive inhibition, incorporation into 
mtDNA causing premature chain termination (i.e. mtDNA deletions), impairment of 
mitochondrial enzymes (i.e. deficiency in electron transport chain subunits encoded by 
mtDNA, or a direct effect of NRTIs on adenylate kinase and ADP/ATP translocase), 
uncoupling of oxidative phosphorylation and triggering of mitochondria-induced 
apoptosis [28]. Didanosine and stavudine are most likely to cause hyperlactataemia and its 
combination should be avoided, whilst those on abacavir, lamivudine and emtricitabine 
are least likely to do so [5].   
Impaired synthesis of mitochondrial enzymes, that generate ATP by oxidative 
phosphorylation, may cause neuropathy associated with stavudine, didanosine, zalcitabine 
and myopathy associated with stavudine [26, 27]. Concurrent use of zidovudine and 
stavudine is best avoided as intracellular activation of stavudine is inhibited [5].  
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Stavudine exhibits preferential inhibition of viral reverse transcriptase with relatively low 
inhibition of host cell DNA polymerase. Initial clinical studies showed significant 
antiviral effects displayed by stavudine with acceptable safety [30]. However, its use is 
now discouraged due to long-term toxicity such as lipoatrophy (of face and limbs), 
hypertriglyceridaemia and neuropathy [4]. Fat redistribution with stavudine use may 
present itself as loss of subcutaneous fat, facial wasting, truncal adiposity, enlarged breast 
and buffalo hump [8]. There have been reported cases of increased morphological changes 
when used in combination with lamivudine [31]. Clinical and metabolic abnormalities 
associated with stavudine use are partially reversible upon drug withdrawal or substitution 
[32]. Saint-Marc et al. analysed the levels of plasma triglycerides and pyruvate when 
stavudine was either substituted with zidovudine (ZDV) and lamivudine (3TC) (NRTI 
group) or ZDV/ ABC (PI group). After 6 months of discontinuation, plasma triglycerides 
dropped by 46% and 36% in the two groups respectively, and pyruvate levels dropped by 
37.5% and 20.8% respectively [32]. 
There are serious dose-limiting adverse-effects associated with didanosine, which include 
peripheral neuropathy and pancreatitis. They occur more often in patients with higher 
doses, renal failure and advanced HIV infection. Frequent GI discomfort with didanosine 
use should be treated with caution, as it may be a sign of evolving pancreatitis [5, 29].  
 
Lamivudine is generally well tolerated with relatively fewer adverse-effects. The most 
common experienced are diarrhoea, malaise, fatigue, headache and sleep disturbances. 
This drug is primarily excreted via the kidneys therefore doses must be adjusted 
accordingly in patients with renal dysfunction [33].  
Drug hypersensitivity reactions, commonly experienced in HAART patients, are 
associated with all NNRTIs, abacavir and amprenavir. The rash usually begins one to 
three weeks after initiation and manifests as an erythematous, maculopapular, pruritic rash 
with or without fever [26]. An estimated 5% of patients initiated on abacavir experience 
hypersensitivity reactions within the first 6 weeks of treatment necessitating 
discontinuation if experienced [34, 35].  
Tenofovir is known to be nephrotoxic and should be used with caution in patients with 
renal dysfunction as it may cause renal impairment, proteinuria and Fanconi Syndrome [5]. 
Gallant et al. [36] showed a small but statistically significant change in creatinine clearance 
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with tenofovir use. These changes may not be clinically significant in patients with 
normal renal function at baseline, however they may become significant if renal 
impairment is present [36, 37]. Tenofovir is also associated with osteopaenia (more so than 
stavudine) and mild to moderate GI effects [5, 38].  
Approximately 5-10% of HAART patients experience anaemia or granulocytopaenia due 
to bone marrow suppression caused by zidovudine. Other adverse-effects may include, 
nausea, anorexia, headache, and fatigue. A decrease in the recommended dose of 
zidovudine has shown improved tolerability [26, 34, 39].  
1.4.3 Protease inhibitors (PI) 
PIs inhibit the protease enzyme, thereby preventing the cleavage of viral proteins and 
resulting in immature, non-infectious HIV viral particles [5]. PIs may cause metabolic 
abnormalities, such as hypercholesterolaemia, hypertriglyceridaemia, and insulin 
resistance. The lopinavir/ ritonavir combination is most commonly associated with 
diarrhoea, lipodystrophy and metabolic disorders [5]. 
Regimens that included indinavir were discontinued due to renal colic, a common side-
effect of the drug. This is due to indinavir being poorly water-soluble resulting in its 
crystallisation in urine and causing an obstruction between the renal tubules and urethra. 
In vitro studies have shown that indinavir can inhibit lipogenesis and this may occur via 
altered retinoid acid signaling [26, 40].  
Atazanavir and indanivir inhibit the uridine diphosphate glucoronyl transferase (UGT) 
1A1 enzyme, which causes interference with the metabolism of bilirubin and may lead to 
jaundice or scleral icterus. In a study by Molina et al. of atazanavir/ritonavir versus 
lopinavir/ritonavir, 4% of the atazanavir arm had grade 2-4-jaundice and/ or icterus [29, 41].  
 
1.4.4 Integrase inhibitor (INSTI) 
 
Integrase is an enzyme essential for viral replication and catalyzes two reactions that 
mediate the insertion of reverse-transcribed viral genome into the host DNA. Therefore 
INSTIs inhibit integration and viral replication in cells [33]. Common adverse-effects of 
INSTI (RAL) include, headache, insomnia, dizziness and fatigue [29]. 
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1.4.5 CCR5 antagonists 
CCR5, a chemokine, acts as a major co receptor for HIV-1 entry in the cell. CCR5 
antagonist therefore blocks HIV-1 entry and infection of cells [34]. At clinical doses of 
maraviroc, vicriviroc and aplaviroc, common adverse-effects include: headache, nausea, 
cramps, flatulence and diarrhoea. In vitro studies demonstrate good tolerability of these 
drugs [7].  
1.4.6 Fusion inhibitor 
 
The known drug in this class enfuvirtide (T-20) targets a step in viral entry. It inhibits 
conformational change in HIV-1 transmembrane glycoprotein (gp41) that is necessary for 
the fusion of HIV-1 and target cell membranes [37]. Known adverse-effects of enfuvirtide 
are injection site reactions, hypersensitivity reactions and pneumonia [29]. 
 
Since integrase inhibitors, CCR5 antagonists and fusion inhbitors are relatively new, not 
much is known about the long-term adverse-effects of these drugs. 
 
1.5 Metabolic Syndrome (MetS) 
 
Metabolic syndrome is defined as a group of risk factors used to identify an individual’s 
susceptibility in developing cardiovascular disease or type 2 diabetes [42]. In 1988 
“Syndrome X” was proposed by G.M. Reaven [43] and was later known as insulin 
resistance syndrome. He noted patients with a cluster of abnormalities who were at higher 
risk for cardiovascular disease. The term “metabolic syndrome” originated when WHO 
and the Adult Treatment Panel III of the National Cholesterol Education Program (ATP 
III/NCEP) proposed criteria, which enabled the identification of patients with an 
increased risk of cardiovascular disease [43]. The cluster of components of metabolic 
syndrome confers a risk beyond that of the sum of individual components [43]. Metabolic 
syndrome has varying criteria selected by different bodies such as the WHO, ATP III and 
International Diabetes Federation (IDF), all of which allude to the same cardiovascular 
risk [41].  Various clinical definitions led to confusion amongst clinicians when it came to 
identifying patients with metabolic syndrome. The IDF and American Heart Association/ 
National Heart, Lung, and Blood Institute (AHA/NHLBI) representatives therefore met in 
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an attempt to reconcile the different definitions and released the interim joint statement 
including various bodies harmonizing the definition of metabolic syndrome [44].  
The components of metabolic syndrome include (Table 4): central obesity, raised fasting 
glucose, raised blood pressure, dyslipidaemia i.e. raised triglycerides (TG) and lowered 
HDL-c [44].   
 
1.6 Clinical Criteria for Diagnosing Metabolic Syndrome 
Table 4: Clinical markers used to diagnose metabolic syndrome by different bodies [44-46] 






Men: > 102 
cm 
Women: > 88 
cm 




Men: ≥ 94 cm 
Women: ≥ 80 cm 




≥ 1.70 mmol/L ≥ 1.70 mmol/L OR 












Men: < 0.90	  mmol/l 
Women: < 1.00 
mmol/L 
Men: < 1.00 mmol/L 
Women: < 1.30 
mmol/L 
 




≥ 140/ ≥90 mmHg ≥ 130/≥ 85 mmHg 
OR drug treatment in 









≥ 5.55 mmol/L OR 




-Those with normal 
glucose levels (<6.1 
mmol/L) glucose 
uptake below 













Between 20-25% of the global adult population is estimated to have MetS and are twice 
as likely to die from, and three times more likely to suffer from heart attack or stroke in 
comparison with people without MetS [45, 47].   
Side-effect profiles of certain antiretroviral agents match the markers of MetS and have 
thus been implicated in its pathogenesis. Prevalence of metabolic syndrome among HIV-
infected patients globally ranges from 17.0% to 45.4% and 10% to 21% in Sub Saharan 
Africa (Table 5) [48-52].  
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1.7 Global Prevalence of MetS 
 
Table 5: Prevalence of metabolic syndrome in HAART patients by studies conducted 
in different countries [23, 48, 42- 60] 
Area Prevalence Year Reference 
Barcelona 17% 2005 53 
Italy 20.8% 2007 54 
New South Wales, 
Australia 
ATP: 7.8%                   
IDF: 8.5% 
2007 55 
Taiwan 26.2% 2011 52 
Colorado 20% 2012 56 
Brazil 30% 2013 57 
Cameroon NCEP: 30.7%                 
IDF: 32.8% 
2013 58 
Southern Ethiopia ATP: 18.1%                 
IDF: 25% 
2014 23 
Miami 30% 2015 59 
Burkina Faso 18% 2015 48 
South West Uganda Male: 58%              
Female: 62% 
2016 60 
The risk of metabolic syndrome increases with age and varies between ethnicities [56]. 
Prevalence of metabolic syndrome may also be dependent on sex, the population 
surveyed, genetic predisposition and lifestyle (e.g. diet and level of physical activity) [61]. 
Persons with metabolic syndrome are not only susceptible to cardiovascular disease and 
diabetes, but are also predisposed to conditions such as cholesterol gallstones, fatty liver, 
polycystic ovary syndrome and some forms of cancer [46].   
PIs are strongly associated with metabolic syndrome, however recent studies show that all 
classes of HAART are associated with the syndrome to varying degrees [52]. It has been 
shown that the prevalence of metabolic syndrome increases with duration of exposure to 
HAART [52]. Stavudine has the highest association with metabolic syndrome and HIV-
related fat accumulation [50, 51].  
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1.8  Components of MetS in HIV Patients on HAART 
1.8.1 Abnormal fat distribution  
Lipodystrophy is a broad term used to describe metabolic disturbances characterised by 
various manifestations of fat redistribution that may occur as complete or partial loss of 
adipose tissue of the extremities (lipoatrophy) and/or central adipose tissue accumulation 
(lipohypertrophy) [42, 73]. After the introduction of HAART, there were reports of changes 
in body fat accumulation, particularly central fat accumulation (abdominal obesity) and 
lipoatrophy of the arms, legs and face [62]. It was then classified into a syndrome of 
peripheral lipoatrophy with central hypertrophy, particularly associated with PI use [43]. 
Lipoatrophy in HIV-infected patients is characterized by loss of subcutaneous fat in the 
face, buttocks and extremities. This results in the appearance of sunken cheeks, 
exaggerated musculature, bones, arteries and veins. Lipohypertrophy is characterised by 
truncal obesity, dorsocervical fat accumulation and breast enlargement [63, 64].   
Common metabolic abnormalities found in HAART-associated lipodystrophy patients 
are: hyperglycaemia, hyperinsulinaemia, hypercholesterolaemia, and 
hypertriglyceridaemia [65].  Exposure to PIs, duration of NRTI/ PI use, increase in age, 
gender, duration and severity of HIV-disease, viral load and extreme changes in BMI 
have been recognised as potential risk factors [65]. 
Various pathways have been postulated in the pathophysiology and etiology of HIV-
associated lipodystrophy. Occurrence of HIV-Associated Lipodystrophy Syndrome 
(HALS) is a result of complex interactions of viral factors and antiretroviral agents [65]. 
The effects of HAART on adipose tissue could be associated with a local inflammatory 
state via the increased production of pro-inflammatory cytokines (tumor necrosis factor 
alpha (TNF-α), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1)) and 
the decreased level of adiponectin. Adipocyte metabolism is controlled by these pro-
inflammatory cytokines, which decrease adiponectin production and induce insulin 
resistance, leading to increased lipolysis. The broken down free fatty acids are poorly 
metabolised by other tissues and result in lipotoxicity, i.e. triglyceride depots with liver 
steatosis, Very Low-Density Lipoprotein cholesterol (VLDL-c) overproduction, muscle 
intramyocellular fat depots and the onset of insulin resistance. The progressive 
accumulation of TNF-α may play a role in metabolic changes as it inhibits the uptake of 
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free fatty acids by adipocytes via the suppression of lipoprotein lipase activity leading to 
fat wasting (TNF-α and other pro-inflammatory cytokines impair PPARγ expression and 
promote adipocyte lipolysis) [42, 65]. 
Previously, HIV-infected patients experienced a wasting syndrome, however central 
weight gain and peripheral fat loss with HAART use is becoming more prevalent. The 
peripheral fat loss/ wasting should be distinguished from other wasting conditions 
associated with HIV e.g. AIDS wasting syndrome, cachexia, malnutrition, adrenal 
insufficiency and severe chronic infections [65]. A study done at the University of 
Alabama by Tate et al. [66] noted that after a 6-month period, patients who were prescribed 
a PI exhibited a significant increase in BMI. There was an increase in overweight patients 
from 24% to 31% over a 24-month period. Within the same period the prevalence of 
obesity increased from 20% to 25% [66]. A study done by Krishnan et al. highlighted the 
significant role of body mass index on metabolic syndrome after antiretroviral initiation. 
Patients with a high BMI at antiretroviral initiation were less likely to improve their 
metabolic syndrome status and could be at heightened risk for the onset of cardiovascular 
disease [56].  
Central obesity is a key factor to meet the IDF definition of the metabolic syndrome [63, 
64]. However, the occurrence of central obesity is controversial as certain data collected on 
patients with peripheral lipoatrophy supports the concept that during fat loss, visceral fat 
is relatively spared, giving the impression of increased abdominal girth, hence 
pseudotruncal obesity [63]. Hyperlipidaemia together with central obesity have been 
associated with a higher incidence of arteriosclerosis [67].  
The development of fat wasting is enhanced when PIs and NRTIs are used together. This 
overlapping toxicity may be due to mitochondrial dysfunction as PI-associated insulin 
resistance and increased fatty acid flux may affect mitochondrial function. Mitochondrial 
toxicity is prominently associated with NRTI use and thus may have a synergistic effect 
when used together [68]. Abdominal subcutaneous lipoatrophy is a possible reason for 
certain HIV-infected patients not being diagnosed with metabolic syndrome, as they do 
not meet the waist circumference criterion. Lipoatrophy results in a lower body mass 
index and cannot be a reliable substitute for waist circumference and has led to discussion 
toward a possible recalibration of these parameters for HIV-infected persons [43]. 
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J Miller et al. [69] observed that patients taking only NRTIs had different symptoms of 
lipodystrophy as opposed to patients taking both NRTIs and PIs. Patients on NRTIs and 
PIs had presented with symptoms of peripheral fat loss and abdominal distension. The 
NRTI group was associated solely with lipoatrophy of which these patients had additional 
symptoms of higher lactate and alanine aminotransferase, lower albumin, cholesterol, 
triglyceride and insulin levels [64, 69]. It is known that metabolic and body-fat abnormalities 
are common among HIV-infected adults receiving nucleoside-analogue and PI therapy. 
There is preliminary evidence that suggests that these patients have an increased risk of 
cardiovascular disease [70]. 
NRTIs have been associated with alterations in body fat deposition and metabolic 
alterations, particularly changes in serum triglyceride concentrations. These alterations are 
less evident in patients using tenofovir + lamivudine as opposed to those using 
zidovudine/ didanosine/ stavudine + lamivudine [25, 71]. The NRTI most strongly 
associated with lipoatrophy is stavudine with a 30% incidence of over a 2-year period, 
particularly when used together with didanosine [14, 70].  
 
The aetiology of lipodystrophy includes the alteration of mitochondrial function, 
specifically with NRTI use [72]. Mitochondrial toxicity is associated with prolonged use of 
NRTIs leading to lactic acidosis [5]. The mechanisms involved in mitochondrial toxicity 
include: competitive inhibition, incorporation into mitcochondrial DNA (mtDNA) leading 
to premature chain termination, impairment of mitochondrial enzymes, uncoupling of 
oxidative phosphorylation and triggering of mitochondrial-induced apoptosis [28].  
Mitochondrial DNA polymerase, essential for mtDNA replication, is acutely sensitive to 
NRTIs. mtDNA encodes genes for vital enzymes of the respiratory oxidative 
phosphorylation electron transport chain [65]. Inhibition of mtDNA polymerase leads to 
mtDNA depletion, respiratory chain dysfunction with subsequent toxicity and reduced 
energy production [27, 73]. mtDNA is crippled by NRTI use, which leads to lactate 
accumulation and subsequent development of lactic acidosis. This is a potent trigger of 
adipocyte death and leads to lipodystrophic changes [65, 73, 74]. Mitochondrial toxicity is 
responsible for pathological changes and irreversible damage to intracellular metabolism 
[75]. Patients with HIV-associated lipoatrophy were found to have a decrease in mtDNA 
levels by a mean of 44% [73]. Factors contributing to mitochondrial toxicity may be: 
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underlying organ dysfunction, concomitant HIV-1 opportunistic diseases and 
administration of drugs with similar toxicity profiles [26]. 
A retrospective study by Aldeen et al. [76] found that 16% of patients on nevirapine and 
two NRTIs developed lipodystrophy. All these cases were associated with an undetectable 
HIV-1 RNA levels. Self-reports by patients revealed symptoms of peripheral fat loss and 
central obesity [76]. Recent data shows powerful anti-adipogenic effect of EFV in cultured 
adipose cells, suggesting its ability to cause fat wasting [77].  
PIs were thought to be the reason behind early clinical cases of lipodystrophy [42, 78]. Carr 
et al. found that after two years of potent PI containing therapy, lipodystrophy was very 
common and was rated severe by 11% of patients. Lipodystrophy was progressive in most 
cases and did not resolve spontaneously [79].  
PIs bind to the catalytic region of HIV-1 aspartyl protease with approximately 60% 
homology with the sequence of the lipid binding domain of the Low-Density Lipoprotein 
Receptor (LDL-R) such as, Low-Density Lipoprotein Receptor-related Protein (LRP) and 
C-terminal region of Cellular Retinoic-Acid Binding Protein type 1 (CRABP-1)[78, 80]. 
LRP binds to LPL and hydrolyses free fatty acids, promoting accumulation in adipocytes. 
Remnants of triglyceride-rich proteins are removed from circulation by the LDL receptor 
[42]. PIs bind to LRP on the capillary endothelium and interfere with the LRP-LPL 
complex [42]. This leads to a reduced cleavage of fatty acids from circulating triglycerides 
by the LRP-lipoprotein lipase complex and reduced hepatic uptake of chylomicrons [67]. 
This results in hyperlipidaemia leading to fat redistribution to the abdomen, insulin 
resistance and type 2 diabetes (in patients who are susceptible) [67]. 
Lipodystrophy associated with PI use is induced by impairing the conversion of retinoic 
acid to cis-9-retinoic acid by: 1) Binding to CRABP-1. This protein facilitates the binding 
of retinoic acid (RA) to nuclear retinoic acid receptors. RA that is bound to CRABP-1 is a 
better substrate for metabolic enzymes than free RA. CRABP-1 binds to intracellular RA 
and facilitates the conversion to cis-9-RA, which is a major ligand for retinoic X receptor 
(RXR). Heterodimerisation of RXRα-PPARγ enhances binding activity of cis-9-RA to 
RXR [65, 67, 73, 78]. PIs inhibit SREBP-1 activation of this heterodimer. Cell culture studies 
and animal studies show PI administration results in an increase in de novo lipogenesis 
and cholesterol synthesis through suppression of SREBP-1 [70, 78]. The cis-9-RA-RXR-
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PPARγ molecular complex rescues adipocytes from apoptosis and increased adipocyte 
differentiation. Inhibition of CRABP-1 results in apoptosis and impaired differentiation of 
peripheral adipocytes. There is relative sparing of intraabdominal and visceral adipocytes 
thereby contributing to the development of changes in fat distribution [65]. 2) Inhibiting 
cytochrome P450-3A isoforms. Inhibition of these isoforms that metabolise RA leads to a 
reduction of RXR stimulation and impaired differentiation of peripheral adipocytes 
resulting in lipid release of decreased lipid storage [67].  
PIs may induce lipoatrophy by inhibiting sterol regulatory enhancer–binding protein 1 
(SREBP1)–mediated activation of the heterodimer consisting of adipocyte retinoid X 
receptor and peroxisome proliferator–activated receptor γ (PPARγ) or related 
transcription factors such as PPARγ coactivator 1. In vitro studies have shown that PIs 
can inhibit lipogenesis and adipocyte differentiation, stimulate lipolysis, and impair 
SREBP1 nuclear localization [70]. 
1.8.2 Dyslipidaemia 
Patients infected with HIV may present with an elevation in total cholesterol, Low-
Density Lipoprotein cholesterol (LDL-c), Triglycerides (TG) and decreased HDL-c levels 
[42]. Abnormal lipid levels are associated with the infection and worsen after the initiation 
of therapy. Viraemia- associated dyslipidaemia includes decreased plasma concentrations 
of total cholesterol, HDL-c and LDL-c and a subsequent increase in plasma triglycerides 
(as a result of impaired clearance of TG-rich proteins) [24]. The presence of abnormal lipid 
levels has been associated with metabolic syndrome resulting from visceral fat 
accumulation with insulin resistance [5, 42].  
During early stages of HIV infection there is a decrease in HDL-c levels and as the 
disease progresses LDL-c levels decrease modestly. With the progression to advanced 
disease, VLDL-c increases. There exists a negative link between HIV RNA and HDL-c 
levels with very high HIV RNA levels being associated with increased triglycerides and 
VLDL-c. Treatment with HAART causes a dissociation of HDL-c and triglycerides. PIs 
were previously associated with comparatively lower HDL-c levels, however newer trials 
showed no change in HDL-c levels in patients treated with ritonavir, lopinavir/ritonavir, 
indinavir, and atazanavir. NNRTIs (nevirapine and efavirenz), on the other hand, increase 
HDL-c levels [43, 81]. Neither of these NNRTIs restores HDL-c to normal levels in patients 
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who begin therapy with HDL-c levels around 25 mg/dL (0.65mmol/L) [43]. 
Ombeni et al. observed an increase in the prevalence of dyslipidaemia in HAART patients 
as CD4 counts began to rise and the viral load was suppressed. They concluded that the 
immune recovery in patients led to an elevation in lipid levels, augmenting the elevation 
caused by HAART [82]. The prevalence of dyslipidaemia in all HAART patients ranges 
from 20-28% depending on the criteria and population investigated. A cross sectional 
DAD study showed the prevalence of hypercholesterolaemia, hypertriglyceridaemia and 
low HDL-cholestrol to be 10-27%, 23-40% and 19-27% respectively, depending on the 
antiretroviral regimen used [72].  
PIs are strongly associated with alterations in lipid metabolism and may cause fasting 
hypertriglyceridaemia and elevated LDL-c. Up to 70% of patients receiving PI therapy 
develop dyslipidaemia and require lipid-lowering therapy such as statins [84]. The 
pathways by which PI-induced dyslipidaemia occurs are not fully understood but 
suppression of nuclear SREBP-1 in the liver has been suggested [72]. Carr et al. [85] 
hypothesized that PI therapy may cause unspecified reactions with proteins that regulate 
lipid metabolism viz. cytoplasmic-acid binding protein type 1 and LRP. The subsequent 
inhibition may be the cause of hyperlipidaemia and contribute to central fat deposition 
and insulin resistance [85]. A study conducted by Calza et al. found that 60% of patients 
who were on a PI-based regimen for 12 months exhibited hypertriglyceridaemia, and 
hypercholesterolaemia was detected in 42.4% [83]. 
Regimens containing potent PIs such as indinavir, ritonavir and nelfinavir cause serum 
lipid alterations in up to 50-70% of patients. Hypertriglyceridaemia occurs in 60-100% of 
these patients, while hypercholesterolemia occurs in 10-70% of patients [86]. Lopinavir 
was also linked to hypercholesterolaemia and hypertriglyceridaemia [87]. 
Tenofovir (NRTI) appears to reduce the levels of non-HDL-cholesterol, LDL-cholesterol 
and total cholesterol [88]. NRTIs including zidovudine, stavudine and lamivudine have also 
become associated with the occurrence of dyslipidaemia via mitochondrial toxicity [80].  
1.8.3 Insulin resistance and glucose intolerance 
Insulin resistance (IR) occurs over time when adipose tissue and skeletal muscle cells 
become less sensitive to insulin. Glucose can no longer be absorbed and remains in the 
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blood triggering the production of more insulin. The demand for increased insulin 
production leads to exhaustion of pancreatic β-cells until the pancreas is unable to 
produce sufficient insulin leading to hyperglycaemia and type 2 diabetes [45]. Non-HIV 
causes of insulin resistance may include; obesity (especially visceral), physical inactivity, 
the use of certain drugs and acute bacterial infection [89]. 
The majority of overweight or obese patients display signs of Insulin Resistance (IR) but 
not all have metabolic disturbances. Central obesity is a key factor in the diagnosis of IR. 
Visceral adipose tissues secrete adipocytokines such as, leptin, resistin, TNF-α and IL-6, 
which induce insulin resistance together with plasminogen activator inhibitor-1. 
Adiponectin is an important adipocytokine responsible for protection against the 
development of type 2 diabetes mellitus, hypertension, inflammation and atherosclerotic 
vascular disease [90]. TNF-α and IL-6 are elevated in HIV infection and influence normal 
suppression of hepatic glucose production and insulin-stimulated glucose uptake. 
Peripheral insulin sensitivity can be indirectly influenced by TNF-α by the stimulation of 
TG and free fatty acid (FFA) production in the liver [91]. 
Intramuscular accumulation of lipids, as a result of lipodystrophy, is associated with 
impaired insulin actions in the skeletal muscle cells. Abnormalities in fat distribution and 
lower extremity lipoatrophy lead to impaired glucose homeostasis. In HIV-infected 
patients the mechanisms of glycaemic dysregulation and associated defects in lipid 
metabolism and secretion are (in part) due to defects in lipid metabolism and 
inflammation, leading to insulin resistance and impaired glucose tolerance / fasting 
glucose [92]. 
The risk of IR in HIV-infected patients may be due to the pro-inflammatory effects of 
HIV and the direct or indirect (e.g. changes in body fat distribution) consequences of 
HAART [93]. HAART impairs glucose tolerance by: 1) the induction of peripheral IR in 
skeletal muscles and adipose tissues, 2) compensatory impairment of pancreatic β-cells 
[93]. Factors contributing to insulin resistance may be PI use, restoration to health, fat and 
aging [89]. There is up to 60% prevalence of IR in HAART patients, depending on the 
criteria and techniques used for diagnosis [72]. Altered pancreatic β-cell function has been 
noted in HIV-1 patients on HAART when compared to controls. This occurred mainly 
with PI exposure, leading to an impairment of glucose sensing with inhibition of insulin 
release [77].  
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Prior to the introduction of PIs, HIV-infected patients generally had normal or decreased 
glucose levels, without the presence of insulin resistance [63]. Since the late 1990s many 
patients on PI-containing HAART regimens developed non-insulin dependent diabetes 
mellitus. This is associated with impaired glucose tolerance, insulin resistance, high 
fasting plasma insulin and C-peptide levels; as well as elevated proinsulin and insulin [42, 
64]. The high prevalence of hyperlipidaemia and insulin resistance associated with PI use 
leads to an increased risk of cardiovascular diseases and diabetes [94]. In vitro research 
shows that PIs can directly impair insulin signalling in insulin-responsive tissues at 
therapeutic doses. However, further investigations are required to elucidate the underlying 
mechanisms in an in vivo context [68]. 
PIs may affect insulin sensitivity by various mechanisms such as insulin receptor 
substrate-1 (IRS-1) phosphorylation and subsequent glucose uptake from adipocytes. 
Lipodystrophy may also result in β-cell dysfunction and is associated with impaired 
feedback of insulin on β-cells [98]. PIs induce IR by reducing insulin-mediated glucose 
uptake by GLUT4, identified as a direct target of PIs. The direct effect on GLUT4 was 
supported by demonstrating blockage of glucose transport in non-insulin sensitive calls 
transfected with GLUT4 [89]. Initial observations of GLUT4 targeting were noted with 
indinavir use which inhibited insulin-stimulated glucose uptake in 3T3-L1 adipocytes but 
did not affect early insulin signalling events or the translocation of intracellular GLUT1 or 
GLUT4 transporter to the cell surface [91]. Indinavir showed a 45% intrinsic inhibition of 
GLUT4 transport activity in a dose-dependent manner. Similar effects on glucose 
transport were demonstrated by other PIs and may be responsible for iatrogenic 
complications seen in these patients [94]. GLUT4 intrinsic transport activity is potently 
decreased by PIs, without substantially affecting early insulin signalling or GLUT4 
translocation [94]. 
Behrens et al. confirmed in their study that there is a complex alteration in glucose and 
insulin metabolism in patients on HAART [85]. It was shown that patients on PIs were 
associated with a higher rate of diabetes mellitus, impaired glucose tolerance and early 
secretion of pro insulin. There were significantly higher rates of disproportional secretion 
of pro insulin and delayed insulin secretion in hyperlipidaemic patients on PIs compared 
to normolipidaemic patients on PIs [85].   
NRTIs have also been linked to alterations in glucose tolerance mediated by 
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mitochondrial toxicity [95, 92]. Munshi et al. assessed the contribution of didanosine to the 
development of diabetes and hyperosmolar nonketotic diabetic syndrome [95]. 
Hyperglycaemia was reported in 82 patients and it was concluded that didanosine 
potentially causes diabetes and hyperosmolar nonketotic diabetic syndrome [95].  
K Samaras et al. [30] evaluated the incidence and prevalence of metabolic syndrome and 
subsequent diagnosis of cardiovascular disease and type 2 diabetes in HIV-infected adults 
over a 3-year period. During this period there was a 5% incidence of type 2 diabetes and 
those who met the criteria for metabolic syndrome at baseline showed an increase risk of 
developing Type 2 Diabetes Mellitus (T2DM). There was also an increased risk of T2DM 
in patients who progressed to metabolic syndrome during their follow-up [30].  
1.8.4 Elevated blood pressure 
Atherogenic effects of certain antiretroviral drugs result in the thickening of the arterial 
wall thus causing hypertension and cardiovascular disease in these patients [96]. PI’s may 
promote the formation of atherosclerotic lesions by increasing CD36-dependent 
cholesterol ester accumulation in macrophages, a scavenger-receptor pathway that is 
thought to mediate the formation of atherosclerotic lesions [70]. Prospective studies of 
hypertension in patients on PIs and NRTIs show no significant increases in blood pressure 
[43]. However, upon examination of individual medication, lopinavir/ritonavir was 
significantly associated with systolic elevation in blood pressure. Systolic hypertension is 
an important predictor of cardiovascular disease and raises concern in patients on a 
lopinavir/ritonavir-containing regimen [97].  
In Malaysia, a cross sectional study showed no significant link between HAART and 
hypertension [96]. Regimens including zidovudine, stavudine and PIs had no statistical 
significance of hypertension. Patients exhibiting a hypertensive state were more likely as 
a result of lifestyle, age and higher BMI/ waist circumference [96]. 
Reports suggest that HAART is associated with an increase in both peripheral and 
coronary arterial diseases [27]. The presence of hypertension is stronger in patients on PIs 
or NNRTIs than those who are treatment naïve [70]. At this stage, NRTIs and PIs cannot be 
linked to hypertension [97]. 
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It is hoped that these metabolic abnormalities that lead to the metabolic syndrome will be 
minimal with FDC use. The study sets out to ascertain whether it is a more favourable 
long-term treatment option. It is hypothesised that FDC use will have a decreased 
prevalence of metabolic syndrome and patients will exhibit more favourable clinical 
markers. 
1.9 Aim 
To investigate the incidence and prevalence of metabolic syndrome in HIV patients on 




1. To determine the incidence and prevalence of metabolic syndrome in patients on 
HAART 
2. To investigate the impact of a single pill compared to triple therapy on the 





CHAPTER TWO: MATERIALS AND METHODS  
 
2.1 Ethical Approval 
 
Application for ethical approval was made to the Biomedical Research and Ethics 
Committee of the University of KwaZulu Natal on 31 March 2016. Provisional ethical 
approval was granted on 08 June 2016 with minor queries. Once all queries were 
addressed, full ethical approval was granted on 11 July 2016. The BREC reference 
number assigned to the aforementioned application is BE227/16. 
 
2.2 Study 
The study was undertaken as a retrospective chart review, with patients that fulfil the 
criteria being randomly selected. Selected patients were all pre-existing HAART patients 
on treatment for the duration of a minimum of 3 years. Relevant data was extracted from 
patient files and collected in the form of a questionnaire. The researcher filled out the 
questionnaires without patient interaction as access was only made to the patient files due 
to the study design. Data collection went as far as back as 3 years starting from 2013 (the 
roll-out of the FDC programme). Clinical data was collected over 3 years with one value 
being recorded per year, as patients have 6-monthly clinic visits. 
2.3 Location 
The study was conducted at Addington Hospital, a National Department of Health facility 
in the central Durban area. A gatekeeper letter was sent to the CEO, Dr. M Ndlangisa, and 
permission was granted on 9 May 2016. Further permission was requested and granted 
from Dr. J Bayat to use the Ikusasa ARV Clinic. 
2.4 Sample Size 
 
Assuming that the prevalence of metabolic syndrome in patients on ARV is 10% and 
using a power of 80% and a confidence level of 95%, a sample size of 196 per group, was 
calculated to detect a difference prevalence of 10% between patients on a fixed-dose 
combination and a triple therapy regimen. The sample size calculation formula used was  
24	  	  
 
2.5 Inclusion Criteria 
 
• Adult patients (patients above the age of 18 years),  
• HIV infected patients who were on HAART for at least 3 years. 
• Males and females 
• All races were included 
• HAART regimens included variations of triple therapy regimens that include 
NRTIs, NNRTIs, PIs (depending on patient specific factors and tolerability) 
• A single pill, which contains efavirenz/tenofovir/emtricitabine. 
 
2.6 Exclusion Criteria 
 
• Patients under the age of 18 years 
• Pregnancy 
 
2.7 Criteria for MetS 
 
The criteria for metabolic syndrome will be in accordance with that of the Joint Interim 
Statement: Any 3 of the following:  
Waist circumference: Men- 94 cm Women 80 cm OR Body mass index ≥ 30.00 kg/m2 
Raised triglycerides ≥ 1.70 mmol/L OR drug treatment for elevated triglycerides 
Reduced HDL-c < 1.0mmol/L in males and < 1.30 mmol/L in females  
Elevated blood pressure ≥ 130/85 mmHg OR antihypertensive drug treatment in a patient 
with a history of hypertension 
Raised fasting plasma glucose ≥ 5.55 mmol/L OR random glucose ≥ 7.80 mmol/L OR 
drug treatment of elevated glucose. 
 
2.8 Data Capture 
 
Data was captured using Microsoft Excel for Mac version 14.2.0 and sent to the 
statistician, Ms. Y Balakrishna (Medical Research Council) to be analysed. 
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2.9 Analysis 
Analysis was done using STATA version 14 (StataCorp., College Station, TX, USA). 
Data was described using means (standard deviation) and frequencies and percentages. 
Associations between categorical variables were tested using either Pearson’s chi square 
test or Fisher’s exact test, where applicable. Differences in continuous variables between 
groups were tested using oneway ANOVA. Univariable and multivariable logistic 
regression was carried out to determine significant predictors of metabolic syndrome in 
patients. Results were significant for p < 0.05. Atherogenic Index of Plasma was 
calculated using the following formula: AIP= log10 (TG⁄HDL-c) [111]. AIP 1, 2 and 3 
were calculated from plasma lipid determinations done at 12 months intervals for all 






























CHAPTER THREE: RESULTS 
 
Of the 350 (n) patients surveyed, all met the inclusion criteria. The majority were female- 
62.6% and 37.4% males, with a collective overall mean age of 41.4 years. Group A 
comprised of the FDC regimen and group B the triple therapy (TT) regimen. From the 
information available there were no pregnant women or family history of chronic 
conditions. There was insufficient evidence as to whether patients were smokers or not 





Figure 1: Age distribution among patients on FDC and TT. 
The highest patient group was within the age range of 26-45 years (64%) and the lowest 
above 66 years of age (2.3%). The mean age was calculated to be 41.4 ± 10.92 years. The 
mean age calculated in both A and B was 40.51 ± 11.11 and 42.33 ± 10.67, respectively. 
There was no association between HAART regimen and age category (p = 0.955) and no 






Figure 2: Gender distribution among patients on FDC and TT. 
Figure 2 shows the numbers of males and females per group. There was no significant 
























Figure 3: Ethnic profiling of patients on FDC and TT. 
The vast majority of patients were Ethnic Black (92.6%), followed by Mixed Ancestry  
(4.3%), Mainland Indian Descent (MID) (2.3%) and Caucasoid (0.9%). There was no 




An equal number of patients were in both group A and B (n=175). All patients within 
group A were on the EFV/FTC/TDF fixed-dose combination. Group B comprised of 
various triple therapy regimens, shown in Figure 4.  
 
Figure 4: Number of patients on variations of triple therapy regimens. 
A total of 146 patients were on a PI-based regimen. The remainder (n = 29) were on a 
regimen consisting of 2 NRTIs + 1 NNRTI. The most common PI-based regimen 
included LPV/r: 77.7% in combination with 3TC and TDF. The variations in regimens 
included: 
Lamivudine (3TC), Zidovudine (AZT), Nevirapine (NVP) 
Lamivudine, Abacavir (ABC), Efavirenz (EFV) 
Lamivudine, Abacavir, Lopinavir/ Ritonavir (LPV/r) 
Lamivudine, Abacavir, Nevirapine 
Lamivudine, Zidovudine, Lopinavir/ Ritonavir 
Lamivudine, Efavirenz, Stavudine (d4T) 
Lamivudine, Tenofovir (TDF), Atazanavir/ Ritonavir (ATV/r) 
Lamivudine, Tenofovir Efavirenz 





A total of 82 patients had comorbidities, 36 of which were in the FDC group and 46 in TT 
group.  There was no significant association found between HAART regimen and the 
generalised presence of comorbidities (p = 0.207). 
 
 
Figure 5: Distribution of patients with comorbidities. 
 (DM = Diabetes Mellitus, HPT = Hypertension, TB = Tuberculosis) 
 
However, upon examining individual comorbidities, hypertension was found to be 
significantly associated with HAART regimen (p = 0.033). Group B had a total of 13.1% 
hypertensive patients and 6.3% in group A. Of those in group B with comorbidities, 17 of 
46 patients had diabetes alone, 12 patients had hypertension alone and those that had a 
combination of diabetes and hypertension made up 15.6% of the total group with 
comorbidities. 
The “other” category comprised of: epilepsy, psychosis, hyperthyroidism, acute renal 
failure, breast cancer, bipolar disorder, peripheral neuropathy and arthritis. 
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3.6 Current medication 
 
A total of 86 patients were on additional medication, most of whom were on 
antihyperglycaemic agents (12.3%) and antihypertensive agents (9.7%). Patients on lipid-
lowering therapy (statins) made up 4.6% of the study population and were not 
significantly associated with HAART regimen (p = 0.306). Patients on “other” medication 
consisted of: beta-agonist inhalers for the treatment of asthma, antiepileptic agents, 
antipsychotic agents, thyroxine, anti-inflammatories and chemotherapeutic agents. 
 
 




Figure 7: Current medication combinations 
1. Antihypertensive agent  
2. Antihyperglycaemic agent   
3. Statin  
4. Anti-tuberculosis agent and  
5. Other 
A higher number of patients were found to be on a combination of medication in group B. 
The most common medication included antihypertensive agents and antihyperglycaemic 
agents. 
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3.7 Mean Values of Clinical Markers 
 
Table 6: Mean values of clinical markers with standard deviation 
 FDC  N TT  N 
Random blood glucose (mmol/L) 5.45 ± 1.99 175 6.06 ± 2.13 175 
Total fasting cholesterol (mmol/L) 4.34 ± 0.95 17 4.81 ± 1.40 152 
HDL- cholesterol (mmol/L) 1.31 ± 0.51 17 1.25 ± 0.37 152 
LDL- cholesterol (mmol/L) 2.23 ± 0.78 17 2.76 ± 1.03 148 
Triglycerides (mmol/L) 1.52 ± 0.79 17 1.75 ± 1.29 151 
BMI (kg/m2) 27.04 ± 5.74 174 27.33 ± 4.82 168 
Systolic Blood pressure (mmHg) 118.27 ± 10.39 175 123.39 ± 10.95 173 
Diastolic Blood pressure (mmHg) 75.07 ± 7.56 175 78.93 ± 6.87 173 
N= number of patients 
 
	  
Figure 8: Mean random blood glucose readings among FDC and TT groups. 
Both groups had glucose readings for all patients (n =175 per group). The mean glucose 






Figure 9: Mean total fasting cholesterol readings among FDC and TT groups. 
Group A had a mean cholesterol value of 4.34 mmol/L ± 0.95 among 17 patients. Group 
B had a mean cholesterol value of 4.81 mmol/L ± 1.40 among 152 patients. Differences in 
mean total fasting cholesterol levels between group A and B were not statistically 






Figure 10: Mean High-Density Lipoprotein cholesterol (HDL-c) among FDC and TT 
groups. 
The mean HDL-cholesterol was higher in group A, 1.31 mmol/L ± 0.51 among 17 
patients, compared to group B, 1.25 mmol/L ± 0.37 among 152 patients. Differences in 






Figure 11: Mean Low-Density Lipoprotein cholesterol (LDL-c) among FDC and TT 
groups. 
The mean LDL-c was higher in group B, 2.76 mmol/L ± 1.03 among 148 patients. Mean 
LDL-c was 2.23 mmol/L ± 0.78, among 17 patients in group A. 4 of the 152 patients with 






Figure 12: Mean triglyceride readings among FDC and TT groups. 
The mean triglyceride readings were 1.52 mmol/L ± 0.79 in group A among 17 patients 
and 1.75 mmol/L ± 1.29 in group B among 151 patients. Differences in mean triglyceride 
levels between group A and B were not statistically significant (p = 0.47). 
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Figure 13: Mean Body Mass Index (BMI) among FDC and TT groups. 
BMI was defined using the WHO criteria, where patients are classified as underweight (< 
18.50 kg/m2), normal (18.5-24.99 kg/m2) overweight (≥ 25.00 kg/m2) and obese (≥ 30.00 
kg/m2).  [49] 
The mean body mass index (BMI) in group A was 27.04 kg/m2 ±	 5.74 and 27.33 kg/m2 ±	 
4.82 in group B. Mean values of BMI between group A and B were not statistically 





Figure 14: Mean systolic and diastolic blood pressure among FDC and TT groups. 
Mean blood pressure readings were taken from 175 patients in both groups. The mean 
systolic and diastolic blood pressure (BP) readings were both higher in the TT group. 
Group A had a mean systolic BP of 118.27 mmHg ±	 10.39 and diastolic BP of 75.07 
mmHg ±	 7.56. Mean systolic and diastolic BP in group B were 123.39 mmHg ±	 10.95 
and 78.93 mmHg ±	 6.87, respectively. Mean systolic and mean diastolic blood pressures 
were positively significantly associated with HAART regimen (p < 0.001). 
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3.8 Prevalence of Metabolic Syndrome (MetS) 
 
 
Figure 15: Prevalence of metabolic syndrome (MetS). 
There was a 16.6% overall prevalence of metabolic syndrome. The prevalence was found 
to be higher with the triple therapy regimen (11.7%) compared to the FDC regimen 
(4.9%).  Odds ratio: 2.84 (confidence interval 1.54-5.24). 
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3.9 Individual Factors compared to MetS 
 
Figure 16: Prevalence of MetS in males and females. 
From the results obtained, there was a higher prevalence of MetS in females compared to 
males. There is a 1.26 times increased likelihood of MetS occurring in a female (p = 
0.022). 
18-25 26-45 46-65 66+ 
Yes 0 28 26 4 













Figure 17: Prevalence of MetS among different age groups. 
Metabolic syndrome most commonly occurred in patients in age groups 26-45 (48.3%) 
and 46-65 (44.8%).  Age was significantly associated with MetS (p = 0.001). 
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Ethnic Black Mixed Ancestry Mainland Indian Descent Caucasoid 
Yes 54 1 3 0 















Figure 18: Prevalence of MetS among different ethnicities. 
Although the patient number for the MID group was low, 3 out of the 8 patients were at 
risk for MetS, the highest prevalence per ethnicity group. It is to be noted that of the 8 
MID patients, 5 had comorbidities. Of the total of 15.4% had MetS in the Ethnic Black 






Figure 19: Prevalence of MetS in the presence of comorbidities. 
A significant percentage of patients (60.3%) with comorbidities had metabolic syndrome. 
Of the group with no known comorbidities, 8.6% had MetS. Presence of diabetes alone 
had the highest prevalence (44.1%), whilst the combined presence of diabetes and 
hypertension had a prevalence of 29.4%. However, more patients were at risk for MetS 
within the group of patients with hypertension and diabetes (83.3%) as opposed to 
diabetes alone (53.6%). 
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Figure 20: Prevalence of MetS among individual comorbidities. 	  
The presence of MetS is almost 1.5 times more in diabetic patients than those without. 










Figure 21: Prevalence of MetS with concomitant medication. 
The highest prevalence of MetS is in the group on antihyperglycaemic agents (60.5%) and 
constitutes as 44.8% of the total number of patients with MetS. There is a 50% split in the 
number of patients on antihypertensive agents with MetS. Patients on antihypertensive 








Figure 22: Prevalence of MetS in WHO categories [49] of BMI. 
Prevalence of MetS gradually increases as BMI increases. The highest incidence of MetS 
was in patients with a BMI ≥ 30.00 kg/m2 (73.2%). There is a significant relationship 
between BMI and the incidence of MetS (p < 0.001). The odds ratio (OR) for every BMI 

























3.10 Atherogenic Index of Plasma 
 
Atherogenic Index of Plasma (AIP) is a calculation of the logarithmic ratio of HDL-c to 


































	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 23: Mean calculated AIP values in the FDC and TT groups over a 3-year period.  
 
AIP was calculated for HDL-c and TG readings taken at yearly intervals for 3 consecutive 
years (AIP 1, 2 and 3). 
The differences between the two treatment groups were not statistically significant. The 
mean AIP values for the TT group were higher than those of the FDC group. Values were 
lower at baseline, increased in the second reading, and returned to near baseline values, 
creating a trend for both groups. (The first reading taken was used as the baseline value).
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CHAPTER FOUR: DISCUSSION AND CONCLUSION 
 
The aim of this study was to investigate the incidence and prevalence of metabolic 
syndrome in HIV patients on HAART triple therapy compared to a fixed-dose 
combination of EFV/FTC/TDF. It was hypothesized that patients on triple therapy would 
have a higher association with metabolic syndrome. The results obtained confirmed this 
statement, with the univariable logistic regression showing almost 3 times the odds of 
developing MetS with triple therapy compared to the FDC. The overall prevalence of 
MetS was 16.6%, consistent with prevalence in sub Saharan African countries [45-49]. The 
findings indicate that significant predictors of MetS were HAART regimen (TT), blood 
glucose, BMI and the presence of comorbidities. There was a marked difference between 
the two groups with respect to: glucose (p = 0.006), LDL-c (p = 0.04), systolic BP (p < 





There were 219 females studied compared to 131 males (Figure 1). The incidence of 
MetS (Figure 16) in the total study population was higher in females (12.5%) compared to 
males (4%). Of the 58 patients that were at risk for MetS, 75.6% were female. The 
likelihood of MetS occurring in females is 1.3 times greater than in males. Gender was 
significantly associated with the incidence of MetS (p = 0.022). The greater prevalence of 
MetS in females than males (regardless of criteria used) was in line with previous studies 
done [56-57, 99, 100, 106]. These studies concurred that being female was significantly 
associated with the development of MetS. Leal et al. found a higher prevalence of MetS in 
females with odds ratios of 2.36:1 using NCEP/ATPII criteria and 2.75:1 using IDF/ 
AHA/ NHLBI criteria [102]. Aside from race and ethnicity, the increased susceptibility of 
developing MetS in females may be due to biological (e.g. hormonal regulation of body 
weight and adiposity), psychological and environmental factors [58, 61]. 
The study population was predominantly middle-aged, with the overall mean age being 
41.4 years of age. There was no significant difference between the mean ages (p = 0.119) 
in both HAART regimen groups. No significant association was found between HAART 
regimen and age category (p = 0.955), however presence of MetS was significantly 
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associated with age (p = 0.001). The prevalence of MetS was highest among patients in 
age groups 26-45 years (48.3%) and 46-65 years (44.8%), consistent with data suggesting 
that risk of MetS increases with age (Figure 17). Patient numbers were, however, highest 
within these age categories, and upon further analysis per category, patients who were 
66+ years of age had a 50% incidence of MetS. Previous studies conducted found 
significant associations between patients ≥ 40 years of age and the presence of MetS [59-60, 
99, 100]. A study by Jerico et al. suggested a significant association between age groups, the 
incidence of MetS was 5.1% in patients < 30 years and 27% in patients between 50-59 
years of age [53]. A directly proportionate relationship between age and risk of MetS has 
been well established.  
 
Most patients were Ethnic Black (92.6%) and the remainder (7.4%) accounted as Mixed 
Ancestry, Mainland Indian Descent (MID) or Caucasoid origin (Figure 3). Due to a large 
disparity in patient numbers, no conclusion could be made regarding the relationship 
between ethnicity and MetS. There was no association found between the choice of 
regimen and ethnicity (p = 0.088). A pattern of higher patient numbers on FDC in the 
non-ethnic black groups was noticed. The Ethnic Black group was the only group to have 
more patients on TT than FDC. This could possibly be due to new initiations on HAART 
treatment, as FDC was only phased in during 2013. Higher numbers of patients in this 
group on TT could have been preexisting patients prior to 2013. Even though there was 
significantly more Ethnic Black than MID patients, the prevalence of MetS within the 
MID group was 37.5%. The overall distribution of MetS among ethnicities was 93.1% of 
Ethnic Black patients, 1.72% Mixed Ancestry patients and 5.17% Indian patients (Figure 
18). There was no incidence of MetS amongst Caucasoid patients. 
 
4.2 Patient Groups (FDC and TT) 
 
A heterogeneous mix of patients on triple therapy was chosen, with regimens being 
tailored to the individual. The objective of the study was to ascertain the difference in the 
incidence and prevalence of MetS in both groups as a whole, and not just one specific 
triple therapy regimen. This was done to demonstrate whether and FDC of EFV/FTC/TDF 
was more favourable with respect to metabolic complications, reaffirming the move 
toward this combination as first-line treatment. Significant differences were found 
between the FDC and TT group. Aside from the higher prevalence of MetS in group B, 
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random blood glucose, LDL-c, triglyceride and blood pressure readings were higher in 
this group. There was an equal distribution (n =175) of patients between the both groups. 
All five clinical markers were not always available for each patient, however a minimum 
of three was always available. Amongst group B, the highest number of patients was on a 
PI-based regimen (n = 146), indicating that the majority of patients on triple therapy were 
on second-line treatment. Although there has been a recall on the usage of stavudine, two 
patients were on a stavudine-based regimen. These patients were older and could have 
been stable on this regimen, hence the continuation. Both patients on the stavudine-based 
regimen had comorbidities including, hypertension and diabetes, and their HDL-c and TG 
levels were within an acceptable range.  
 
4.3 Metabolic Syndrome 
 
MetS was defined using the joint interim statement, which is more inclusive as it accounts 
for gender differences, preexisting conditions, and concurrent medication e.g. statins, 
antihyperglycaemic agents and antihypertensive agents [44]. Overlooking preexisting 
conditions and/ or current medication may be misleading, as clinical markers may be 
controlled and within an acceptable range. This may produce a false impression that these 
markers will not confer a risk. The overall prevalence of MetS was 16.6%, in line with 
sub Saharan Africa (10-21%) statistics [48-52]. Of this percentage, a higher prevalence was 
found group B, 11.7% compared to 4.9% from group A (Figure 15). Among the 58 
patients with MetS, 41 were on TT and 17 on the FDC, confirming the hypothesis. The 
results indicate that the odds of developing MetS are 2.84 times more likely on triple 
therapy compared to the fixed-dose combination. Upon further examination of group B, 
the incidence of MetS was highest among patients on an LPV/r containing regimen 
(87.8%) and constituted 62.1% of all patients with MetS. The use of LPV/r is known to 
have a high association with the incidence of MetS [101].  PIs were initially thought to be 
the only class linked to MetS, and its high association with MetS is demonstrated by the 
results obtained [52]. This reinforces the information on the metabolic adverse-effect 
profiles of different HAART drugs. PIs are known to lead to peripheral lipodystrophy, 
central weight accumulation, hyperlipidaemia, and insulin resistance (some of which were 
noticed within the results) [59]. The use of PIs in group B was a significant contributor to 
abnormal glucose, LDL-c and TG levels. Elevated blood pressure, both systolic and 
diastolic, was significantly noted in the TT group. Of the patients with LDL-c levels 
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available, 4 patients had levels that were too high to calculate. All of them were on a PI-
based regimen, more specifically including LPV/r. The FDC combination of 
EFV/FTC/TDF had better clinical outcomes when compared to TT. 
 
4.4 Comorbidities and Current Medication 
 
The incidence of comorbidities was comparatively higher amongst those in group B 
(56.1%), with the highest incidence occurring in PI-based regimens, and 43.9% within 
group A (Figure 5). This could be as a direct result of treatment, progression of disease or 
underlying factors. There was no significant association found between the incidence of 
comorbidities and HAART regimens (p = 0.207). Of all the patients in the study, the most 
frequently occurring comorbidities were diabetes and hypertension, or a combination of 
both. A total of 81.3% of patients with comorbidities had diabetes, hypertension or both. 
Overall, the presence of multiple comorbidities had no significant relationship with 
HAART regimen (p = 0.278). When comparing between the two groups, the presence of 
diabetes and hypertension was higher among patients in group B (61.4% and 67.7% 
respectively). The incidence of tuberculosis, asthma and diseases classified as other were 
independent of HAART regimen. 
 
The presence of comorbidities had a significant relationship with the risk of MetS (p < 
0.001). 60.3% patients with comorbidities had MetS and 39.7% had no incidence of MetS 
(Figure 19). From the results obtained, the presence of comorbidities is found to be a 
significant contributor to MetS. There was a 29.4% incidence of MetS among patients 
with diabetes and hypertension. With diabetes or hypertension occurring as the only 
comorbidity, the incidence of MetS was 44.1% and 11.8%, respectively. Among all 
diabetic patients, there was a 61.4% incidence of MetS (p < 0.001). The high number of 
diabetic patients with MetS is expected, as diabetes is one of the end points of MetS [42]. It 
is probable that these patients would have exhibited components MetS prior to being 
diagnosed as diabetic, however this cannot be confirmed from the available data. It is 
important to note that not all individuals with MetS will develop diabetes as some may 
only develop cardiovascular disease. Among patients with hypertension, 50% had MetS 
(p < 0.001). TB, asthma and conditions classified as other, had no association with the 
incidence of MetS. 
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Patients on concurrent medication made up 24.6% of the total study sample (Figure 6). 
All patients who were diagnosed as diabetic or hypertensive were on appropriate 
treatment for these conditions. There were 16 patients on lipid lowering therapy, all of 
which were on a statin. Of these 16 patients, 50% of them were on a PI-based regimen 
including LPV/r. Statins are used primarily to reduce LDL-c levels, although their effects 
are beyond lipid-lowering as they also aid in the prevention of cardiovascular disease [24]. 
This is particularly useful in patients with MetS, however statins should be taken 
cautiously in patients on PIs and NRTIs as they are metabolised by the same pathway 
(CYP 3A4) and may affect bioavailability [24]. 
Although there were two patients recorded with TB, only one of the patients was recorded 
under anti-TB therapy. From the information at hand, the appropriate treatment was not 
found in the patients file, however this does not necessarily mean that the patient was not 
treated for this indication. Taking the setting into account, it is not uncommon for a 
patient to have multiple files, depending on the clinic they are visiting and thus may have 
been recorded elsewhere.  
 
The presence of concurrent medication had a significant association with the incidence of 
MetS (p = 0.005). When each category was looked at individually, patients on 
antihyperglycaemic agents, antihypertensive agents and statins had a significant 
association with the incidence of MetS (Figure 21). 
There was a 50% split between patients on antihypertensive agents and those who were 
not with respect to the incidence of MetS (p < 0.001). Patients on antihyperglycaemic 
agents had a 60.5% incidence of MetS (p < 0.001). Patients on statin therapy had the 
highest incidence of MetS (75%) among them (p < 0.001). There was no significant 
association between patients on other current medication and the incidence of MetS (p = 
0.300). 
 
4.5 Clinical Markers 
 
The clinical markers studied in these patients were random blood glucose, cholesterol, 
HDL-c, LDL-c, TG, systolic BP, diastolic BP and BMI. The mean value for each marker 
was calculated from the number of patients with available clinical readings (Table 6). The 
mean values for all the aforementioned markers were higher in group B, with the 
exception of HDL-c, which was higher in group A. Significant differences were found 
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when comparing the two groups, with respect to, glucose (p = 0.006), LDL-c (p = 0.04), 
systolic BP (p < 0.001) and diastolic BP (p < 0.001). These clinical markers were 
classified as risk factors if: random glucose ≥ 7.8 mmol/L, blood pressure ≥ 130/85 
mmHg, HDL-c < 1.00 mmol/L in males and < 1.30 mmol/L in females, triglycerides 
≥1.70mmol/L and BMI ≥ 30.00 kg/m2. The overall mean TG value (1.72 mmol/L) and 




Statistical analysis showed a significant relationship with blood glucose levels and 
HAART regimens (Figure 8). In the clinic setting, fasting blood glucose was not 
frequently tested due to impracticality; therefore random blood glucose was instead 
tested. Mean random blood glucose values were higher in group B (6.06 mmol/L) than 
group A (5.45 mmol/L). The results indicate that there is just over a 2 fold increased odds 
of MetS with every unit increase from the mean glucose. There was a significant 
relationship found between elevated blood glucose values and MetS (p < 0.001). 
Hyperglycaemia is a marker for insulin resistance and in the presence of glucose 
tolerance, leads to elevated blood glucose and development of diabetes mellitus [105]. 
Majority of patients on PI-based regimens with MetS were either diabetic or had elevated 
blood glucose levels. PIs are known to play a role in the development of insulin 
resistance, via the reduction in glucose uptake by GLUT4 [89]. Previous studies have 
shown that PIs, IDV and LPV/r, can cause insulin resistance and may be reversible upon 
discontinuation [101]. Clinically, these results are confounded by the fact that the blood 
glucose is a random measurement, and reflects postprandial blood glucose. 
 
4.5.2 HDL- Cholesterol and Triglycerides 
 
The information available for cholesterol was limited as not all patients had their lipid 
profiles done routinely. Jacobson et al. found that low HDL-c and high TG levels were the 
most common criteria used to diagnose MetS [104]. From the information available, mean 
HDL-c levels were 1.31 mmol/L and 1.25 mmol/L in group A and B, respectively (Figure 
10). There was no significant relationship found between HDL-c levels and HAART 
regimen (p = 0.061) and could possibly be due to gaps in information. 
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The mean triglyceride levels were significantly positively associated with HAART 
regimen (p = 0.023) (Figure 12). Group B had a mean TG level of 1.75 mmol/L, which 
was higher than the acceptable range (values ≥1.70 mmol/L were considered a risk for 
MetS). Between group A, the mean TG level was lower than group B, 1.52 mmol/L. A 
study by Riddler et al. found untreated HIV-infected patients had lower HDL-c and LDL-
c levels compared to controls and after HAART initiation the changes in levels were not 
significant. However, triglyceride levels were elevated in the presence of untreated HIV-
infected patients and were significantly increased after HAART initiation, suggestive of a 
direct result of treatment [107]. Factors that may also lead to the elevation in TG levels 
include: current or history of severe immune depression, time since HIV diagnosis and 
presence of opportunistic infections [31]. Dyslipidaemia is characterised by elevated TG, 
LDL-c, total cholesterol and decreased HDL-c levels and is associated with HAART 
treatment [24, 42, 57]. Between the patients who were at risk for MetS, 69% had a total 
cholesterol ≥ 4.50 mmol/L and 70.7% had LDL-c levels ≥ 2.59 mmol/L. Patients in group 
B on a PI-based regimen had a higher prevalence of elevated total cholesterol, TG, LDL-c 
and decreased HDL-c, putting them at risk of dyslipidaemia. Lipid abnormalities 
commonly occur within the first 12 months of HAART treatment and progressively 
worsen over time. Ritonavir is known to have a significant effect on total cholesterol and 
TG levels, leading to hyperlipidaemia [31].  
 
The atherogenic index of plasma (AIP) is used by clinicians to calculate the risk of 
cardiovascular disease and may be used as a predictor of atherosclerosis. The high 
predictive value of AIP may be owing to its strong correlation with lipoprotein particle 
size. The ratio of HDL-c to triglycerides has been shown to be a strong predictor of 
myocardial infarction [109, 110]. AIP is defined as the base 10 logarithm of the ratio of TG 
to HDL-c (mmol/ L). The suggested risk categories for AIP are, low < 0.11, intermediate: 
0.11-0.21, high > 0.21. 
Using the mean TG and HDL-c levels in group A and B, the AIP calculated was 0.06 
(low) and 0.15 (intermediate), respectively. Of the patients who were considered at risk 
(AIP > 0.21), 74.5% had MetS, suggesting an increased risk of developing of 
cardiovascular disease. Of the patients in group B that presented with features of MetS 
calculated AIP, suggested that 14.6% were at low risk, 9.8% were at an intermediate risk 
and 75.6% were at high risk of developing cardiovascular diseases. On the other hand, 
patients in group A that presented with features of MetS, 20% were at low risk, 10% at 
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intermediate risk and 70% were at high risk of developing cardiovascular diseases. Even 
though there were no statistically significant differences between FDC and TT patients, 
these results suggested that patients treated with the EFV/FTC/TDF FDC had a lower risk 
of cardiovascular events (Figure 23). 
 A general trend was observed in both groups, with AIP values starting low, increasing 
over time and eventually decreasing closer to the baseline values (initial reading taken) 
(Figure 23). Higher risk values in group B compared to group A may be due to the FDC 
slowing down the progression to MetS. 
It is evident from the AIP calculations that HAART use and MetS contribute to the 
increased likelihood of adverse cardiovascular events.  
 
4.5.3 Body Mass Index 
 
Body mass index is used to categorise patients as underweight, normal, overweight or 
obese, using weight and height. Body mass index is calculated as an individuals weight 
(kg) divided by their height squared (m2). According to WHO guidelines, an individual is 
classified as overweight if BMI ≥ 25.00 kg/m2 and ≥ 30.00 kg/m2 as obese [49]. Waist 
circumference was not routinely done on patients and therefore could not be used as a 
marker.  The mean BMI calculated varied between the two groups, being higher in group 
B. Mean BMI in group A was 27.04 kg/m2 and 27.33 kg/m2 in group B. The incidence of 
MetS was significantly associated with BMI readings (p < 0.001). Patients who had a 
BMI of ≥ 30.00 kg/m2 had a 73.2% incidence of MetS (Figure 22). The mean BMI 
amongst these patients was 32.54 kg/m2. From the results it can be concluded that there 
1.29 increased likelihood of MetS with every unit increase in BMI. Studies have shown a 
high association between BMI and MetS [53, 102]. Fat gain may be due to restoration of 
health after HAART initiation, however these effects occur initially, followed by possible 
peripheral fat wasting (notably with thymidine analogues) [101]. The use of BMI as a risk 
factor has limitations such as, being unable to distinguish between fat and lean mass and 
not taking into account distribution of body fat [103]. In addition, a person may be within 
the acceptable BMI range but still have metabolic alterations; alternatively a person with a 
BMI ≥ 30.00 kg/m2 may have no metabolic alterations [49]. To ensure accuracy of risk 
factors, a Body Adiposity Index (BAI) has been proposed, however its effectiveness in 
identifying MetS is yet to be ascertained [103].  
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4.5.4  Blood Pressure 
 
Both mean systolic (p = 0.071) and mean diastolic (p = 0.168) blood pressures had no 
significant association with MetS. They were, however, significantly associated with 
HAART regimen (p < 0.001). The overall mean of systolic and diastolic blood pressure 
was 120.82 mmHg and 76.99 mmHg respectively (Figure 14). Mean blood pressure 
values were higher in group B than group A. As blood pressure readings increase by a 
factor, there is an increased likelihood of MetS by 14.3% with systolic BP and 21.6% 
with diastolic BP. Elevations in both systolic and diastolic BP were noticed among 
Cameroonian patients and had a significant relationship with MetS (p < 0.0001) [58]. 
Previous studies suggest that a higher BMI could serve as an explanation for elevated BP 
[59]. Blood pressure elevation due to HAART has been observed by some studies, however 
many others did not confirm a correlation between the two [108]. Prospective studies have 
noted an increase in blood pressure readings, particularly with LPV/r, whereas those on 





Increased periods of exposure to HAART may lead to cardiovascular diseases therefore 
patients should be screened for fasting blood glucose and lipid profiles prior to initiation 
of therapy. Regular follow-ups should be encouraged and adhered to in order to monitor 
clinical markers [100]. Non-pharmacological intervention may be implemented, e.g. proper 
diet and exercise, to help decrease the chances of developing MetS. A proper diet, to 
ensure reduction in body mass, should include adjusted caloric intake, diversification of 
meals, reduced intake of simple sugars and animal fat and increased intake of vegetables, 
fruit, fish and fibre-rich products [75].  
Patients with deranged lipid profiles may be treated with lipid lowering agents. HAART-
associated dyslipidaemia is difficult to manage due to potential interactions between 
drugs, intolerance and low patient adherence. There are several alternatives in the 
treatment of HAART-associated dyslipidaemia e.g. inhibitors of intestinal cholesterol 
absorption, statins, fibrates, fish oil and niacin [80]. 
Current practices in the treatment of  MetS in patients on HAART include the option of 
switching antiretroviral agents. Switching from PIs to NNRTI’s or NRTI’s may partly 
57	  	  





The purpose of the study was to investigate the incidence and prevalence of MetS in HIV 
patients on HAART triple therapy compared to a fixed-dose combination. The results 
obtained indicate a significantly higher incidence and prevalence of MetS among patients 
on a triple therapy regimen compared to a fixed-dose combination of EFV/FTC/TDF. 
Significant differences in patients’ clinical markers (higher in those a triple therapy 
regimen) were noted. Blood glucose, LDL-c and blood pressure readings were markedly 
elevated in patients on triple therapy. When adjusted for age, gender, comorbidities and 
clinical markers, multivariable logistic regression found the significant predictors of MetS 
to be: HAART regimen, glucose, BMI and the presence of comorbidities. It can be 
concluded that the risk of MetS is not solely dependent on HAART regimens, but rather 
based on a combination of individual (genetic and lifestyle) factors, the progression and 
impact of the HIV disease and HAART. The results may also serve as evidence so as to 
augment the move toward using the EFV/FTC/TDF fixed-dose combination as first-line 
treatment due to its lower prevalence of MetS. Aside from the advantages of decreased 
pill burden and cost, the scientific evidence suggests that long-term use of the 




4.8 Study Limitations and Recommendations 
 
The shortcomings encountered included lack of information available on patients. There 
were insufficient fasting blood glucose results available and random glucose had to be 
used. Waist circumferences were not routinely done in HIV patients, however BMI was 
frequently recorded and thus used. I would recommend that a similar study be done 
prospectively, to ensure more stringent adherence to the definition of MetS. A prospective 
study will allow follow up and better availability of information. Lipid profiles were not 
available for all the patients in both treatment groups as this test is reserved for patients 
who require lipid monitoring (due to disease states or risk factors) and patients on PIs. In 
order for more accurate conclusions to be made, it is recommended that all patients have 
lipid profiles ordered for them when studied prospectively. Since the risk factors are 
multifactorial, patient factors that can be controlled, e.g. initiation date of HAART, should 
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Appendix 2: Data collection tool 
DATA COLLECTION TOOL 
PATIENT PARTICULARS        
CODE: ________ 
 
AGE 1. 18-25 3. 45-65 DATE OF BIRTH    
2. 25-45 4. 65 + 
GENDER 1. Male  2. Female  
ETHNICITY 1. Ethnic 
Black 
 2. Mixed 
Ancestry 




                                                    4. Caucasoid  5. Other   
SMOKER 1. Yes  2. No  
IF YES, AMOUNT 
SMOKED PER DAY 
1. 1-5  2. 5-10  3. > 10  
PREGNANT 1. Yes   2. No  
CURRENTLY EMPLOYED 1. Yes  2. No  
COMORBIDITIES 1. Yes  2. No  
IF YES, SPECIFY 1. Diabetes  2. Hypertension  3. TB  











 5. Other  
ANTIRETROVIRAL REGIMEN 1. FDC  2. Triple 
therapy 
 
IF TRIPLE THERAPY, SPECIFY REGIMEN: 
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DOES THE PATIENT CONSUME 
ALCOHOL  
1. Yes  2. No  
IS THERE A FAMILY HISTORY OF 
CHRONIC ILLNESS? 




Date:     
Random 
Glucose 
≥ 7.80 mmol/L 
     
Blood Pressure 
≥ 130/85 mmHg 















     
BMI 
≥ 30 kg/m2 
 
     
 
 
DOES THE PATIENT MEET THE CRITERIA 
FOR METABOLIC SYNDROME 
1. Yes  2. No  
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Appendix 3: Gatekeeper letter  
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  FDC AIP 1 TT AIP 1 FDC AIP 2 TT AIP 2 FDC AIP 3 TT AIP 3 
Number of values 10 41 6 39 4 24 
              
Minimum -0.3800 -0.6100 -0.4200 -0.2400 -0.5700 -0.3200 
25% Percentile -0.2025 0.0400 0.0525 0.0800 -0.3875 -0.1450 
Median 0.0750 0.3000 0.4050 0.3900 0.2050 0.1250 
75% Percentile 0.3300 0.5050 0.5925 0.5300 0.5950 0.4950 
Maximum 0.6100 1.270 0.6900 1.190 0.7100 1.180 
              
Mean 0.0840 0.2834 0.3083 0.3391 0.1375 0.2018 
Std. Deviation 0.3335 0.3434 0.4025 0.3103 0.5296 0.4052 
Std. Error 0.1055 0.05364 0.1643 0.04969 0.2648 0.08272 
              
Lower 95% CI of mean -0.1546 0.1750 -0.1140 0.2385 -0.7052 0.03073 
Upper 95% CI of mean 0.3226 0.3918 0.7307 0.4397 0.9802 0.3729 
              
Sum 0.8400 11.62 1.850 13.23 0.5500 4.844 
 
